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Abstract
Background: Hyaluronic Acid (HA) has been already approved by Food and Drug Administration (FDA) for
osteoarthritis (OA), while its use in the treatment of tendinopathy is still debated. The aim of this study was to
evaluate in human rotator cuff tendon derived cells the effects of four different HA on cell viability, proliferation,
apoptosis and the expression of collagen type I and collagen type III.
Methods: An in vitro model was developed on human tendon derived cells from rotator cuff tears to study the
effects of four different HA preparations (Ps) (sodium hyaluronate MW: 500-730 KDa - Hyalgan®, 1000 kDa
Artrosulfur HA®, 1600 KDa Hyalubrix® and 2200 KDa Synolis-VA®) at various concentrations. Tendon derived cells
morphology were evaluated after 0, 7 and 14 d of culture. Viability, proliferation, apoptosis were evaluated after 0,
24 and 48 h of culture. The expression and deposition of collagen type I and collagen type III were evaluated after
1, 7 and 14 d of culture.
Results: All HAPs tested increased viability and proliferation, in dose dependent manner. HAPs already reduce
apoptosis at 24 h compared to control cells (without HAPs). Furthermore, HAPs stimulated the synthesis of collagen
type I in a dose dependent fashion over 14 d, without increase in collagen type III; moreover, in the presence of
Synolis-VA® the expression and deposition of collagen type I was significantly higher as compare with the other HAPs.
Conclusions: HAPs enhanced viability, proliferation and expression of collagen type I in tendon derived cells.
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Background
Non-traumatic rotator cuff tears are the most common
shoulder joint disease, and have age-associated inci-
dence, since they are favored by the co-presence of
metabolic diseases such as diabetes, thyroid disorders
and hypercholesterolemia [1–4]. Conservative treatment
of tendinopathies has been increasingly supported by
scientific evidence over the last twenty year [5]. Despite
decades of study for HA in the conservative treatment
of osteoarthritis [6], poor evidence is present in the
literature about the indication of this drug for tendino-
pathies [7]. During tendinopathy and tendon acute rup-
ture has been reported an higher incidence of tenocyte
apoptosis and decreased collagen synthesis [8]. Failure
of the healing response may occur in genetically-
predisposed patients, decreasing the resistance of ten-
don structures to mechanical load, resulting eventually
in tendinopathy, or a tendon tear [4, 9, 10].
Hyaluronic acid (HA) (or “hyaluronan”, or “sodium hya-
luronate preparation”) is a high molecular weight glycosa-
miniglycan consists of the repetition of a disaccharide unit
of an N-acetyl-glucosamine and a β-glucuronic acid [11].
Its most important physicochemical properties are its cap-
acity to retain water, having a very high hydration ratio,
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and its visco-elasticity. These two properties are, however,
interdependent. Changes in HA concentrations within
the extracellular matrix modulate a variety of cellular
functions, such as cell migration [12, 13], adhesion
[14, 15], and proliferation [16–18]. Several important
medical applications of HA have been discovered for
joints degeneration [7]. Additionally, high local concen-
tration of HA causes release of endogenous growth fac-
tors and stimulates cell–cell interaction, resulting in
faster cell proliferation during early stages of in vitro
culture. Additional effects reported in clinical animal
studies are related to an accelerated healing process in
the tendons after repair, and decreased scar formation
within the tendons. There has been a lack of specific
studies on human shoulder derived cells. Much of the
study, has been limited by the lack of the exact pheno-
type of the tendon derive cells, moreover, the pattern of
gene expression is consistent with the presence of
mixed population. [19]. Clinical studies in patients with
rotator cuff disease ranging from tendinopathy to rotator
cuff tears detected a positive influence on the reduction of
pain and improved function with no consistent side-
effects recorded. Despite the increased awareness of the
effective role of HA in regenerative medicine, the thera-
peutic use of HA for tendinopathies has been poorly stud-
ied on human tenocytes in vitro.
In this study, was evaluated the effect of four differ-
ent HAPs by molecular weight on viability, metabolic
activity, apoptosis and collagen type I and collagen
type III expression on human rotator cuff tendon tears
derived cells.
Methods
All the procedures described in this investigation were
approved by the Ethical Committee of Rome Tor
Vergata University. All the patients gave written in-
formed consent to be included in the present study.
Tendon samples were harvested from healthy area
close to degenerative supraspinatus tendons tear area
biopsy specimen in 10 patients were operated arthros-
copically for shoulder rotator cuff repair, with a mean
age of 63,6 ± 6,9 years. Trauma history, heavy smoking
habit or systemic conditions such as thyroid disorders,
diabetes, gynecological condition, neoplasia, rheumatic
diseases, and any previous or concomitant rotator cuff
disease were considered exclusion criteria.
Tendon cell cultures
Primary human tendon derived cell cultures were estab-
lished as previously described [20]. In brief, cells were iso-
lated from tissue sample by washing several times with
phosphate buffered saline Dulbecco’s W/O Ca and Mg
(PBS) + 1 % penicillin/streptomycin (Invitrogen, Life Tech-
nologies, Carlsbad, CA, USA). Small pieces of fresh
tendon isolated were carefully dissected and mechanically
disaggregated with the aid of fine watchmaker forceps to
maximize the interface between tissue and medium. Fi-
nally, the tendons were immediately placed on Petri
dishes of 60 mm in diameter (Greiner CELLSTAR dish,
Sigma- Aldrich, Saint Louis, MO, USA), containing
5 mL of α-MEM supplemented with 20 % heat-
inactivated foetal calf serum (FCS) and 1 % L-glutamine
and 1 % penicillin/streptomycin (Gibco, Invitrogen, Life
Technologies) at 37 °C in 5 % CO2 and air with a change
medium every 2–3 d. Tenocytes were then harvested by
StemPro Accutase (Life technologies Carlsbad, CA,
USA), and centrifugated at 1,500 rpm for 5 min when
the cells migrated out of tendon pieces and reached
60–80 % of confluence (19 day). Collected tendon de-
rived cells were immediately used for culture to avoid
phenotype drift with further in vitro passages [21]. The
phenotype of the tendon derived cells had not demon-
strated significant drift as evidence by the gene expres-
sion pattern by assessing the expression of gene for
scleraxis and genes for collagens α1(I), α2(I) and
α1(III) in real-time PCR assays with specific primers
(data not shown).
Tenocyte viability and proliferation
In vitro proliferation was determined by the Alamar Blue
assay. This test was used to measure the metabolism rate
of the cells. The tendon derived cells were seeded with
5×103 vital cells per well in a 96-well plate (Greiner CELL-
STAR dish, Sigma-Aldrich), and in triplicates in 100 μl of
α-MEM supplemented with 10 % FCS . Cells were cul-
tured as previous described [20]. Briefly, after 24 h, cul-
tured cells were exposed to 4 different hyaluronic acid:
Hyalgan MW 500–730 KDa, Artrosulfur HA® MW 1000,
Hyalubrix® MW 1600 KDa, Synolis-VA® MW 2200 KDa,
their features are shown in Table 1. Three different doses
of Hyalgan or Artrosulfur HA® (250 μg/ml, 500 μg/ml and
1000 μg/ml), one doses of Hyalubrix® or Synolis-VA®
(1000 μg/ml). HAPs were dissolved in the same culture
media used for the entire experiments (α-MEM supple-
mented with 10 % FCS) and the Ph was adjusted to 7. Un-
treated cells were used as control. All the cells (HAPs
treated and untreated) were cultured in 1 ml of medium.
Alamar blue dye test (Serotec, Oxford, UK) was per-
formed to assess cell viability after 0, 24, and 48 h of cul-
ture, as previous described [16]. The absorbance was read
spectrophotometrically at 570 and 600 nm wavelengths by
MicroPlate reader (BioRad, Hercules, CA). The results,
obtained as optical density (OD) data, were processed fol-
lowing manufacturer’s instructions and expressed as re-
duction percentage. The calculation of the of the
percentage of alamar blue reduction is as follows accord-
ing to the manufacture’s protocol:
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εoxλ2ð Þ Aλ1ð Þ − εoxλ1ð Þ Aλ2ð Þ of test agent dilution
εredλ1ð Þ A’λ2ð Þ − εredλ2ð Þ A’λ1ð Þ of untreated positive growth control
 100
In the formula ελ1 and ελ2 are constant representing
the molar extinction coefficient of alamar blue at
540 nm and 630 nm, respectively, in the oxidized (εox)
and the reduced (εred) forms. Aλ1 and Aλ2 represent ab-
sorbance of test wells at 540 nm and 630 nm, respect-
ively. A’λ1 and A’λ2 represent absorbance of negative
control wells at 540 and 630 nm, respectively. The
values of % alamar blue reduction were corrected for
background values of negative controls containing
medium without cells.
Finally, in parallel trypan blue exclusion assay was per-
formed. The tendon derived cells were seeded with 104
vital cells per well in a 24-well plate (Greiner CELLSTAR
dish, Sigma-Aldrich), and in triplicates in 1 ml of α-MEM
supplemented with 10 % FCS. After 0, 24 and 48 h the
cultures were detached, collected and counted (Nikon In-
struments INC., Melville, NY, USA) in the Burker cham-
ber with vital dye Trypan Blue (Stem Cells Technologies,
Vancouver, Canada) to evaluate cell viability.
Apoptosis induction
Hydrogen peroxide (H2O2) was used as an inducer of
apoptosis as previously described [22]. The tendon de-
rived cells were seeded with 105 vital cells per well in a
6-well plate in 4 ml of α-MEM supplemented with 10 %
FCS. After 24 h, the medium was removed, and the cul-
tured cells were treated with H2O2 (2 mM) in α-MEM
and 10 % FCS with or without Hyalgan®, Artrosulfur
HA®, Hyalubrix® and Synolis-VA® (1000 μg/ml) for a fur-
ther 24 h. A negative control was prepared by incubating
cells in the absence of both inducing agent and HAPs.
The PE Annexin V/Dead Cell Apoptosis Kit with SYTOX®
Green for Flow Cytometry (Invitrogen, Life Technologies)
was used to detect apoptosis by flow cytometry, cells were
harvested, and processed according to the manufacturer's
instruction. This product detects the externalization of
phosphatidylserine in apoptotic cells using recombinant
annexin V conjugated to the orange fluorescent phycobili-
protein R-PE, and dead cells using SYTOX® Green nucleic
acid stain. After treatment with both probes, apoptotic
cells show orange fluorescence, dead cells show green
fluorescence, and live cells show little or no fluorescence.
Fluorescence-activated cell sorting analysis was carried
out using a FC500 flow cytometer (FL1 and FL3 de-
tector in a log mode) using the CXP analysis software
(Beckmann Coulter, FL, USA).
Immunofluorescence staining
The tendon derived cells were seeded with 5×103 vital
cells per well in a 2-well chamber slides (Thermo Fisher
Scientific, Inc., Rochester, NY, USA), in triplicates and
cultured as previous described [23]. After 1, 7 and 14 d
of culture the tendon derived cells were fixed with pure
acetone for 10 min at −20 °C. Then, washed a few mi-
nutes with PBS. Cells were incubated for 30 min at room
temperature with PBS containing 5 % of Bovine Serum
Albumin (BSA) (Kedrion Group S.P.A., Lucca, Italy) for
protein blockage. Primary antibodies for Anti-type I
(1:2000), Anti-type III collagen molecules (1:500)
(Sigma-Aldrich), and secondary antibodies fluorochrome
were diluted in PBS containing 5 % BSA. Cells were in-
cubated overnight at 4 °C with primary antibodies, 1 h
with the appropriate secondary antibody fluorochrome
at room temperature and then washed a few times with
PBS containing 5 % BSA. Molecule’s staining Alexa
Fluor 488 (Life Tecnologies) was used for type I collagen
and Alexa Fluor 568 (Life Tecnologies) for type III colla-
gen. After washing with PBS plus 5 % BSA, slides were
mounted with 25 μL VECTASHIELD® Hard Set Mounting
Medium and then were examinated with ECLIPSE Ti-U
inverted, fluorescent microscope (Nikon Instruments INC.,
Table 1 Features of Hyaluronic Acids preparations tested
Commecial
Name
Hyalgan® Artrosulfur HA® Hyalubrix® Synolis-VA®
Active Substance Linear Sodium Hyaluronate Linear Sodium
Hyaluronate
Linear Sodium Hyaluronate Linear Sodium Hyaluronate + Sorbitol (4 %)
(limits the HA degradation)
Molecular Weight 600–730 KDa 1000 KDa 1600 KDa 2000 KDa
Source Rooster Combs Bacterial
Fermentation
Bacterial Fermentation Bacterial Fermentation
Doses Tested 250 μg/ml 250 μg/ml 1000 μg/ml 1000 μg/ml
500 μg/ml 500 μg/ml
1000 μg/ml 1000 μg/ml
Manufacturer Fidia Farmaceutici s.p.a.,




Abano Terme (PD), Italy
Anteis s.a., Geneva, Switzerland
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Melville, NY, USA). For image analysis all digital images
were captured with NIS-Elements Imaging Software (Nikon
Instruments INC.). As previously described [23, 24], slides
were examined independently by two experienced operator
and one researcher, with a double-blind method. The total
fluorescence intensity of the area ≥ 10 frames from each
slides was determined. The intensity level was normal-
ized with the control cells untreated. Fully automated
image analysis improve the accuracy of detection and
categorization of collagen staining, making this tech-
nique more sensitive, specific and thus suitable for use
in quality assurance results.
Statistical analysis
Data are typical results from a minimum of three repli-
cated independent experiments and are expressed as
mean ± SD. Comparison of individual treatment was
conducted using Student’s t test. Statistical significance
in comparison with the corresponding control values
was indicated by *P < 0.05 versus control.
Results
Tendon derived cells viability
Tendon derived cells morphology was evaluated under a
light microscope at 0, 7 and 14 d. The cells maintained
their normal, bipolar, spindle shape and cell processes,
during the whole study period for each of the sets of cul-
ture conditions; cellular morphology remained unaltered
for up to 14 d in all the experimental groups (Fig. 1a). Re-
sults from the trypan blue exclusion assay showed that
none of the HAPs reduced cell viability (Fig. 1b). After
48 h of exposure, living cells are in similar numbers when
exposed to HAPs compared to the control. Metabolic
tests provide some information concerning the activity of
cells (Fig. 1c). Alamar blue confirmed an increase in the
metabolic activity of tendon derived cells for all the HAPs
utilized, when compared to untreated cells (Fig. 1c). In
particular, all HAPs induced cell-activity most effectively
at 1000 μg/ml (Fig. 1c, Table 2). The highest increase was
obtained at 48 h for all the HA treatments. However, as
reported in Fig. 1c, there are no significant statistical dif-
ferences between all the various HAPs.
Fig. 1 Effects of Hyalgan®, Artrosulfur HA®, Hyalubrix® and Synolis-VA® on morphologic change cell viability and cell metabolic activity. Tendon
derived cells were treated with different concentrations of Hyalgan, Artrosulfur HA®, Hyalubrix® and Synolis-VA® for different time periods. a. after
treatment for 14 d the morphology of the cells treated with all the HAPs was photographed (1000ug/ml). Magnification, ×100. b. Absolute number of
live cells was calculated using trypan blue exclusion. c. Cell metabolic activity was evaluated with the Alamar Blue method. All tests and determinations
were repeated in triplicate. The metabolic activity rate was calculated by subtracting the background OD value (complete culture medium without cells)
from the OD value from each test well (see materials and methods section). Hyalgan®, Artrosulfur HA®, Hyalubrix®, Synolis-VA® increased cell activity in a
concentration-dependent pattern and with regard to time. No statistically significant difference were observed from control according to Student's t test
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Apoptosis induction
To verify whether or not they counteracted apoptosis in
tendon derived cells, the Annexin V experiment was
performed. Cells were plated and H2O2 induction was
performed for 24 h to induce apoptosis. Concurrently,
tendon derived cells were separately exposed (or not, for
the untreated sample) to Hyalgan®, Artrosulfur HA®,
Hyalubrix®, and Synolis-VA® (1000 μg/ml). Staining cells
simultaneously with PE-Annexin V (red fluorescence)
and the non-vital dye, Sytox Green (green fluorescence),
allowed, using bivariate analysis, discrimination between
intact cells (Annexix V−Sytox Green−), early apoptotic
(Annexix V+Sytox Green−) and late apoptotic (Annexix
V+Sytox Green+) and necrotic cells (Annexix V−Sytox
Green+) (Fig. 2a). The treatment of tendon derived cells
with Hyalgan®, Artrosulfur HA®, Hyalubrix®, or Synolis-
VA® (all at 1000 μg/ml) caused a sizable decrease in
apoptosis, as clearly shown in Fig. 2b. The percentage of
vital cells, at 24 h following Hyalgan®, Artrosulfur HA®,
Hyalubrix®, or Synolis-VA® exposure, increased com-
pared to the control (33.14, 24.01, 36.31, 33.04 and
22.25 % respectively) (Annexix V−, Sytox green−; bottom
left quadrant) (Fig. 2c, Table 2).
Immunofluorescence staining
Next, we determined and measured the type of collagen
deposited by tendon derived cells after stimulation with
Hyalgan®, Artrosulfur HA®, Hyalubrix®, or Synolis-VA®.
Collagen accumulation was evaluated by immunofluor-
escent staining of cells cultured on chamber slides. Fur-
thermore, the expression of collagen type I was higher in
Synolis-VA® than in the presence of Hyalgan®, Artrosulfur
HA®, or Hyalubrix®, and was significantly higher compared
to untreated cells used as a control (Fig. 2a, b). In detail,
immunofluorescent staining at day 7 only revealed pro-
duction of collagen type I from the tendon derived cells in
intracytoplasmic staining (Fig. 3a). Moreover, at day 14 ex-
pression and production of Collagen type I had increased
in the Hyalgan®, Artrosulfur HA®, Hyalubrix® and Synolis-
VA® (Fig. 3a, b). Moreover, Synolis-VA® induced the
most significant expression of collagen type I after 14 d
Table 2 Summary of results
METABOLIC ACTIVITY
Cells 0 h 24 h 48 h
Untreated 22,25 % ± 1,1 % 23,18 % ± 1,3 % 26,69 % ± 0,1 %
Hyalgan® 250 μg/ml 23,68 % ± 0,9 % 26,92 % ± 1,4 %
Hyalgan® 500 μg/ml 25,37 % ± 2,2 % 27,14 % ± 1,9 %
Hyalgan® 1000 μg/ml 25,54 % ± 1,2 % 27,71 % ± 1,3 %
Artrosulfur HA ® 250 μg/ml 24,13 % ± 1,1 % 27,16 % ± 1 %
Artrosulfur HA ® 500 μg/ml 25,47 % ± 1,8 % 27,7 % ± 1,7 %
Artrosulfur HA ® 1000 μg/ml 26,9 % ± 1,5 % 28,55 % ± 1,4 %
Hyalubrix® 1000 μg/ml 26,85 % ± 1,9 % 28,56 % ± 1,9 %
Sinolis -VA® 1000 μg/ml 27,44 % ± 2,2 % 28,58 % ± 2,1 %
APOPTOSIS
Cells Live cells Early Late
Proliferant control 91,2 % ± 0,2 % 1,8 % ± 0,2 % 4 % ± 0,8 %
Apoptotic control 20,5 % ± 0,7 % 10,9 % ± 0,1 % 66,8 % ± 0,1 %
Hyalgan® 1000 μg/ml 31,2 % ± 9,4 % 12,4 % ± 2,5 % 54,4 % ± 7,1 %
Artrosulfur HA ® 1000 μg/ml 20,7 % ± 8 % 9,2 % ± 0,2 % 66,8 % ± 0,7 %
Hyalubrix® 1000 μg/ml 34,9 % ± 6,7 % 11,2 % ± 1,3 % 52,4 % ± 5,3 %
Sinolis -VA® 1000 μg/ml 31,3 % ± 3,5 % 12 % ± 1,7 % 55 % ± 1,9 %
MEAN GREEN INTENSITY
Cells Day 0 Day 7 Day 14
Untreated 0,5 4,2 ± 0,9 8,6 ± 1
Hyalgan® 1000 μg/ml 6,7 ± 1,1 12,3 ± 1,3
Artrosulfur HA ® 1000 μg/ml 6,4 ± 1,5 12,4 ± 1,3
Hyalubrix® 1000 μg/ml 8,9 ± 2,2 10,9 ± 2,1
Sinolis -VA® 1000 μg/ml 8,6 ± 2,5 16,1 ± 3
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(Fig. 3, Table 2). Collagen type III was not found to be
present in any culture conditions (data not shown).
Discussion
These results suggest a binary role for HA on tendon
cells - directly, on tendon derived cells metabolic activ-
ity, and on tenocyte Collagen type I production. It was
highlighted that Hyalgan, Artrosulfur HA®, Hyalubrix®
and Synolis-VA® regulate cell activity of tendon derived
cells. All HAPs increased cell-metabolic activity and
most effectively at 1000 μg/ml and at 48 h (Fig. 1c). HA
modulate a number of biological process including cell
apoptosis. The results show a decrease rate of the apop-
tosis when the tendon derived cells were exposed to the
Fig. 2 The apoptosis rate in tendon derived cells. a. The apoptosis was induced with H2O2 (apoptotic control cells [ACtrCs]) and treated with
Hyalgan®, Artrosulfur HA®, Hyalubrix® and Synolis-VA® (1000 ug/ml). Apoptosis rate of cells in each sample were detected in a population of
10,000 cells analyzed by flow cytometry. b. The percentage of apoptotic cells in Hyalgan®, Artrosulfur HA®, Hyalubrix® and Synolis-VA® decreased
compared to the proliferate control cells (PCtrCs) (without HA). Flow charts: (A1), upper left quadrant annexin V-negative and sytox green-positive
cells indicate necrotic cells; (A2), upper right quadrant, annexin V and sytox green -positive cells represent late apoptotic cells. (A3), lower left
quadrant annexin V-negative and sytox green-negative cells indicate live cells; (A4), lower right quadrant, annexin V positive and sytox green-negative
cells represent early apoptotic cells. Both early and late apoptotic cells were calculated as the incidence of apoptotic cell. The numbers indicate
percentage of total gated cells (mean ± S.D.; n = 3). c. % of cells population of live cells, early apoptotic cells, late apoptotic cells and necrotic cells.
Graph showing the average % of results obtained in 3 independent experiment. No significant differences were detected (mean ± S.D.; n = 3)
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HAPs. Collagen metabolism has been reported to be af-
fected by HA [25, 26]. HA stimulated the synthesis of
collagen type I, in a dose dependent manner over 14 d.
This increase in expression leads to collagen synthesis
and accumulation. It should be noted that Synolis-VA®
induced the most significant expression of collagen type
I at 14d of culture. In contrast, no HAPs induced any
expression of collagen type III, which is normally less
abundant in tendons, and only increases in concentra-
tion during the early phase of remodeling [27] and in
tendinopathy [20, 28]. The lack of collagen type III pro-
duction under HA stress should be considered a protect-
ive factor for tendons. The results obtained are consistent
with a previous study of Yamada and coworkers, even if a
different methods focused directly on the collagen type I
and III proteins was used [29].
Considering the results of this study, the three differ-
ent molecular weight of HAPs tested seems not exert
any effects on tendon derived cells in vitro, while is clear
the essential importance of the concentrations and of
the timing of exposure. The most significant expression
of collagen type I at 14 d of culture of Synolis-VA® can
be explained to the presence of Sorbitol (4 %) that limits
the HA degradation, allowing an higher local concentra-
tion of the drug. Translating these considerations in the
clinical practice, HA are effectives on human tenocytes
and extracellular matrix of rotator cuff, with no essential
differences among HA available in the market. There are
many biological questions that remain to be answered,
and translational factors to resolve. Although, this in vitro
model shows some role played from HA on tendon de-
rived cells, the study have some limitations. First of all,
probably these results cannot be generalized for other ten-
don derived cells from other sources; furthermore in vitro
environment, rich of nutrients and oxygen is very different
from the diseased environment. The complexity of the
extracellular matrix of tendons and its relationship with
tenocytes during physiological homeostasis, disease and
Fig. 3 Collagen type I, expression of tendon derived cells in vitro culture isolated from 9 healthy patients, and staining as described in material and
methods, section Immunofluorescence Staining. Representative images from 4 independent experiments. a. Expression of collagen type I after 7 and
14 d of culture in green fluorescence and in regular light image showing the tendon derived cells. b. Quantization of the immunohistochemistry in a.
Synolis-VA® induced the expression of collagen type I significantly after 14 d of in vitro culture. The mean fluorescent intensity/pixel was measured and
expressed to the corresponding tendon derived cells. Collagen type I Intensity (Total Area was quantified by anti-collagen type I) it was measured by
Nikon software. Data are expressed as mean ± SD for 4 independent experiments for samples run in triplicate. Scale bar (a.): 50 μm
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healing process, attest that is reductive to investigate only
the effect of HAPs on collagen type I and III. As soon as
possible there is need to widen the knowledge of the ef-
fects of HAPs on the main proteins of the extracellular
matrix of tendons.
Despite we tested the three different molecular weight
HA, perhaps more HAPs and different concentration
need to be tested in the same way we did to confirm
which should have the best in vitro results.
Obviously, it is advocate randomized control studies
on the use of HA in the conservative treatment of ten-
dinopathy and in selected patients with rotator cuff
tears, in order to understand and clarify best timing,
doses, intervals of injections and, finally, full clinical
confirmation of effectiveness.
Conclusion
In conclusion, HAPs in dose dependent manner but not
related to the molecular weight, induces increase of cells
activities, decrease of apoptosis of tendon derived cells
Collagen type I protein secretion. Taken together, these
results strengthen a physiological role of HA in the
homeostasis of tendons and has implications for regen-
erative medicine.
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